Search

Your search keyword '"Mikhailidis, Dimitri P."' showing total 272 results
Start Over Author "Mikhailidis, Dimitri P." Publication Year Range Last 3 years
272 results on '"Mikhailidis, Dimitri P."'

1. New-Onset Diabetes Mellitus in COVID-19: A Scoping Review

Author

Pantea Stoian, Anca, Bica, Ioana-Cristina, Salmen, Teodor, Al Mahmeed, Wael, Al-Rasadi, Khalid, Al-Alawi, Kamila, Banach, Maciej, Banerjee, Yajnavalka, Ceriello, Antonio, Cesur, Mustafa, Cosentino, Francesco, Firenze, Alberto, Galia, Massimo, Goh, Su-Yen, Janez, Andrej, Kalra, Sanjay, Kapoor, Nitin, Kempler, Peter, Lessan, Nader, Lotufo, Paulo, Mikhailidis, Dimitri P., Nibali, Luigi, Papanas, Nikolaos, Powell-Wiley, Tiffany, Rizvi, Ali A., Sahebkar, Amirhossein, Santos, Raul D., Toth, Peter P., Viswanathan, Vijay, and Rizzo, Manfredi

Published
2024
Full Text
View/download PDF

2. Correction to: New-Onset Diabetes Mellitus in COVID-19: A Scoping Review

Author

Pantea Stoian, Anca, Bica, Ioana-Cristina, Salmen, Teodor, Al Mahmeed, Wael, Al-Rasadi, Khalid, Al-Alawi, Kamila, Banach, Maciej, Banerjee, Yajnavalka, Ceriello, Antonio, Cesur, Mustafa, Cosentino, Francesco, Firenze, Alberto, Galia, Massimo, Goh, Su-Yen, Janez, Andrej, Kalra, Sanjay, Kapoor, Nitin, Kempler, Peter, Lessan, Nader, Lotufo, Paulo, Mikhailidis, Dimitri P., Nibali, Luigi, Papanas, Nikolaos, Powell-Wiley, Tiffany, Rizvi, Ali A., Sahebkar, Amirhossein, Santos, Raul D., Toth, Peter P., Viswanathan, Vijay, and Rizzo, Manfredi

Published
2024
Full Text
View/download PDF

4. Prevalence of statin intolerance: a meta-analysis

Author

Bytyçi, Ibadete, Penson, Peter E, Mikhailidis, Dimitri P, Wong, Nathan D, Hernandez, Adrian V, Sahebkar, Amirhossein, Thompson, Paul D, Mazidi, Mohsen, Rysz, Jacek, Pella, Daniel, Reiner, Željko, Toth, Peter P, and Banach, Maciej

Subjects
Heart Disease, Cardiovascular, Prevention, Atherosclerosis, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lipids, Male, Prevalence, Randomized Controlled Trials as Topic, Risk Factors, Cardiovascular disease, Risk factors, Statin intolerance, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

AimsStatin intolerance (SI) represents a significant public health problem for which precise estimates of prevalence are needed. Statin intolerance remains an important clinical challenge, and it is associated with an increased risk of cardiovascular events. This meta-analysis estimates the overall prevalence of SI, the prevalence according to different diagnostic criteria and in different disease settings, and identifies possible risk factors/conditions that might increase the risk of SI.Methods and resultsWe searched several databases up to 31 May 2021, for studies that reported the prevalence of SI. The primary endpoint was overall prevalence and prevalence according to a range of diagnostic criteria [National Lipid Association (NLA), International Lipid Expert Panel (ILEP), and European Atherosclerosis Society (EAS)] and in different disease settings. The secondary endpoint was to identify possible risk factors for SI. A random-effects model was applied to estimate the overall pooled prevalence. A total of 176 studies [112 randomized controlled trials (RCTs); 64 cohort studies] with 4 143 517 patients were ultimately included in the analysis. The overall prevalence of SI was 9.1% (95% confidence interval 8.0-10%). The prevalence was similar when defined using NLA, ILEP, and EAS criteria [7.0% (6.0-8.0%), 6.7% (5.0-8.0%), 5.9% (4.0-7.0%), respectively]. The prevalence of SI in RCTs was significantly lower compared with cohort studies [4.9% (4.0-6.0%) vs. 17% (14-19%)]. The prevalence of SI in studies including both primary and secondary prevention patients was much higher than when primary or secondary prevention patients were analysed separately [18% (14-21%), 8.2% (6.0-10%), 9.1% (6.0-11%), respectively]. Statin lipid solubility did not affect the prevalence of SI [4.0% (2.0-5.0%) vs. 5.0% (4.0-6.0%)]. Age [odds ratio (OR) 1.33, P = 0.04], female gender (OR 1.47, P = 0.007), Asian and Black race (P 4 million patients, the prevalence of SI is low when diagnosed according to international definitions. These results support the concept that the prevalence of complete SI might often be overestimated and highlight the need for the careful assessment of patients with potential symptoms related to SI.

Published
2022

5. Artificial intelligence for cardiovascular disease risk assessment in personalised framework: a scoping review

Author

Singh, Manasvi, Kumar, Ashish, Khanna, Narendra N., Laird, John R., Nicolaides, Andrew, Faa, Gavino, Johri, Amer M., Mantella, Laura E., Fernandes, Jose Fernandes E., Teji, Jagjit S., Singh, Narpinder, Fouda, Mostafa M., Singh, Rajesh, Sharma, Aditya, Kitas, George, Rathore, Vijay, Singh, Inder M., Tadepalli, Kalyan, Al-Maini, Mustafa, Isenovic, Esma R., Chaturvedi, Seemant, Garg, Deepak, Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Viswanathan, Vijay, Kalra, Manudeep K., Ruzsa, Zoltan, Saba, Luca, Laine, Andrew F., Bhatt, Deepak L., and Suri, Jasjit S.

Published
2024
Full Text
View/download PDF

6. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).

Author

Penson, Peter E, Bruckert, Eric, Marais, David, Reiner, Željko, Pirro, Matteo, Sahebkar, Amirhossein, Bajraktari, Gani, Mirrakhimov, Erkin, Rizzo, Manfredi, Mikhailidis, Dimitri P, Sachinidis, Alexandros, Gaita, Dan, Latkovskis, Gustavs, Mazidi, Mohsen, Toth, Peter P, Pella, Daniel, Alnouri, Fahad, Postadzhiyan, Arman, Yeh, Hung-I, Mancini, GB John, von Haehling, Stephan, Banach, Maciej, and International Lipid Expert Panel (ILEP)

Subjects
International Lipid Expert Panel, Muscles, Humans, Muscular Diseases, Lipids, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Nocebo Effect, Drucebo effect, Nocebo effect, SAMS, Statin intolerance, Pain Research, Patient Safety, Clinical Research, 6.1 Pharmaceuticals, 7.3 Management and decision making, Management of diseases and conditions, Evaluation of treatments and therapeutic interventions, Musculoskeletal, Physiology, Clinical Sciences, Human Movement and Sports Sciences
Abstract

Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3-5%). Many perceived AEs are misattributed (e.g. physical musculoskeletal injury and inflammatory myopathies), and subjective symptoms occur as a result of the fact that patients expect them to do so when taking medicines (the nocebo/drucebo effect)-what might be truth even for over 50% of all patients with muscle weakness/pain. Clear guidance is necessary to enable the optimal management of plasma in real-world clinical practice in patients who experience subjective AEs. In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step-by-step patient-centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long-term compliance with lipid-lowering therapy.

Published
2022

7. Recent advances and controversial issues in the optimal management of asymptomatic carotid stenosis

Author

Paraskevas, Kosmas I., Brown, Martin M., Lal, Brajesh K., Myrcha, Piotr, Lyden, Sean P., Schneider, Peter A., Poredos, Pavel, Mikhailidis, Dimitri P., Secemsky, Eric A., Musialek, Piotr, Mansilha, Armando, Parikh, Sahil A., Silvestrini, Mauro, Lavie, Carl J., Dardik, Alan, Blecha, Matthew, Liapis, Christos D., Zeebregts, Clark J., Nederkoorn, Paul J., Poredos, Peter, Gurevich, Victor, Jawien, Arkadiusz, Lanza, Gaetano, Gray, William A., Gupta, Ajay, Svetlikov, Alexei V., Fernandes e Fernandes, Jose, Nicolaides, Andrew N., White, Christopher J., Meschia, James F., Cronenwett, Jack L., Schermerhorn, Marc L., and AbuRahma, Ali F.

Published
2024
Full Text
View/download PDF

8. An international, multispecialty, expert-based Delphi Consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis

Author

Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Ringleb, Peter Arthur, Brown, Martin M., Dardik, Alan, Poredos, Pavel, Gray, William A., Nicolaides, Andrew N., Lal, Brajesh K., Mansilha, Armando, Antignani, Pier Luigi, de Borst, Gert J., Cambria, Richard P., Loftus, Ian M., Lavie, Carl J., Blinc, Ales, Lyden, Sean P., Matsumura, Jon S., Jezovnik, Mateja K., Bacharach, J. Michael, Meschia, James F., Clair, Daniel G., Zeebregts, Clark J., Lanza, Gaetano, Capoccia, Laura, Spinelli, Francesco, Liapis, Christos D., Jawien, Arkadiusz, Parikh, Sahil A., Svetlikov, Alexei, Menyhei, Gabor, Davies, Alun H., Musialek, Piotr, Roubin, Gary, Stilo, Francesco, Sultan, Sherif, Proczka, Robert M., Faggioli, Gianluca, Geroulakos, George, Fernandes e Fernandes, Jose, Ricco, Jean-Baptiste, Saba, Luca, Secemsky, Eric A., Pini, Rodolfo, Myrcha, Piotr, Rundek, Tatjana, Martinelli, Ombretta, Kakkos, Stavros K., Sachar, Ravish, Goudot, Guillaume, Schlachetzki, Felix, Lavenson, George S., Jr., Ricci, Stefano, Topakian, Raffi, Millon, Antoine, Di Lazzaro, Vincenzo, Silvestrini, Mauro, Chaturvedi, Seemant, Eckstein, Hans-Henning, Gloviczki, Peter, and White, Christopher J.

Published
2024
Full Text
View/download PDF

9. Carotid Plaque-RADS: A Novel Stroke Risk Classification System

Author

Saba, Luca, Cau, Riccardo, Murgia, Alessandro, Nicolaides, Andrew N., Wintermark, Max, Castillo, Mauricio, Staub, Daniel, Kakkos, Stavros K., Yang, Qi, Paraskevas, Kosmas I., Yuan, Chun, Edjlali, Myriam, Sanfilippo, Roberto, Hendrikse, Jeroen, Johansson, Elias, Mossa-Basha, Mahmud, Balu, Niranjan, Dichgans, Martin, Saloner, David, Bos, Daniel, Jager, H. Rolf, Naylor, Ross, Faa, Gavino, Suri, Jasjit S., Costello, Justin, Auer, Dorothee P., Mcnally, J. Scott, Bonati, Leo H., Nardi, Valentina, van der Lugt, Aad, Griffin, Maura, Wasserman, Bruce A., Kooi, M. Eline, Gillard, Jonathan, Lanzino, Giuseppe, Mikhailidis, Dimitri P., Mandell, Daniel M., Benson, John C., van Dam-Nolen, Dianne H.K., Kopczak, Anna, Song, Jae W., Gupta, Ajay, DeMarco, J. Kevin, Chaturvedi, Seemant, Virmani, Renu, Hatsukami, Thomas S., Brown, Martin, Moody, Alan R., Libby, Peter, Schindler, Andreas, and Saam, Tobias

Published
2024
Full Text
View/download PDF

11. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

Author

Acosta, Julio, Al-Khnifsawi, Mutaz, Alnouri, Fahad, Amar, Fahma, Atanasov, Atanas G., Bajraktari, Gani, Banach, Maciej, Gouni-Berthold, Ioanna, Bhaskar, Sonu, Bielecka-Dąbrowa, Agata, Bjelakovic, Bojko, Bruckert, Eric, Bytyçi, Ibadete, Cafferata, Alberto, Ceska, Richard, Cicero, Arrigo F.G., Chlebus, Krzysztof, Collet, Xavier, Daccord, Magdalena, Descamps, Olivier, Djuric, Dragan, Durst, Ronen, Ezhov, Marat V., Fras, Zlatko, Gaita, Dan, Hernandez, Adrian V., Jones, Steven R., Jozwiak, Jacek, Kakauridze, Nona, Kallel, Amani, Katsiki, Niki, Khera, Amit, Kostner, Karam, Kubilius, Raimondas, Latkovskis, Gustavs, John Mancini, G.B., David Marais, A., Martin, Seth S., Martinez, Julio Acosta, Mazidi, Mohsen, Mikhailidis, Dimitri P., Mirrakhimov, Erkin, Miserez, Andre R., Mitchenko, Olena, Mitkovskaya, Natalya P., Moriarty, Patrick M., Mohammad Nabavi, Seyed, Nair, Devaki, Panagiotakos, Demosthenes B., Paragh, György, Pella, Daniel, Penson, Peter E., Petrulioniene, Zaneta, Pirro, Matteo, Postadzhiyan, Arman, Puri, Raman, Reda, Ashraf, Reiner, Željko, Radenkovic, Dina, Rakowski, Michał, Riadh, Jemaa, Richter, Dimitri, Rizzo, Manfredi, Ruscica, Massimiliano, Sahebkar, Amirhossein, Serban, Maria-Corina, Shehab, Abdullah M.A, Shek, Aleksandr B., Sirtori, Cesare R., Stefanutti, Claudia, Tomasik, Tomasz, Toth, Peter P., Viigimaa, Margus, Valdivielso, Pedro, Vinereanu, Dragos, Vohnout, Branislav, von Haehling, Stephan, Vrablik, Michal, Wong, Nathan D., Yeh, Hung-I, Zhisheng, Jiang, Zirlik, Andreas, Colletti, Alessandro, Mancini, John, Marais, David, Moriarty, Patrick, and Cicero, Arrigo Francesco Giuseppe

Published
2023
Full Text
View/download PDF

12. Why do guidelines recommend screening for abdominal aortic aneurysms, but not for asymptomatic carotid stenosis? A plea for a randomized controlled trial

Author

Paraskevas, Kosmas I., Spence, J. David, Mikhailidis, Dimitri P., Antignani, Pier Luigi, Gloviczki, Peter, Eckstein, Hans-Henning, Spinelli, Francesco, Stilo, Francesco, Saba, Luca, Poredos, Pavel, Dardik, Alan, Liapis, Christos D., Mansilha, Armando, Faggioli, Gianluca, Pini, Rodolfo, Jezovnik, Mateja K., Sultan, Sherif, Musiałek, Piotr, Goudot, Guillaume, Lavenson, George S., Jr, Jawien, Arkadiusz, Blinc, Aleš, Myrcha, Piotr, Fernandes e Fernandes, Jose, Geroulakos, George, Kakkos, Stavros K., Knoflach, Michael, Proczka, Robert M., Capoccia, Laura, Rundek, Tatjana, Svetlikov, Alexei S., Silvestrini, Mauro, Ricco, Jean-Baptiste, Davies, Alun H., Di Lazzaro, Vincenzo, Suri, Jasjit S., Lanza, Gaetano, Fraedrich, Gustav, Zeebregts, Clark J., and Nicolaides, Andrew N.

Published
2023
Full Text
View/download PDF

18. Optimal Management of Asymptomatic Carotid Stenosis in 2021: The Jury is Still Out. An International, Multispecialty, Expert Review and Position Statement

Author

Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Antignani, Pier Luigi, Baradaran, Hediyeh, Bokkers, Reinoud P.H., Cambria, Richard P., Dardik, Alan, Davies, Alun H., Eckstein, Hans-Henning, Faggioli, Gianluca, e Fernandes, Jose Fernandes, Fraedrich, Gustav, Geroulakos, George, Gloviczki, Peter, Golledge, Jonathan, Gupta, Ajay, Jezovnik, Mateja K., Kakkos, Stavros K., Katsiki, Niki, Knoflach, Michael, Kooi, M. Eline, Lanza, Gaetano, Liapis, Christos D., Loftus, Ian M., Mansilha, Armando, Millon, Antoine, Nicolaides, Andrew N., Pini, Rodolfo, Poredos, Pavel, Ricco, Jean-Baptiste, Riles, Thomas S., Ringleb, Peter Arthur, Rundek, Tatjana, Saba, Luca, Schlachetzki, Felix, Silvestrini, Mauro, Spinelli, Francesco, Stilo, Francesco, Sultan, Sherif, Suri, Jasjit S., Zeebregts, Clark J., and Chaturvedi, Seemant

Published
2022
Full Text
View/download PDF

19. Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study

Author

Krzemień, Paweł, Kasperczyk, Sławomir, Banach, Maciej, Kasperczyk, Aleksandra, Dobrakowski, Michał, Tomasik, Tomasz, Windak, Adam, Mastej, Mirosław, Catapano, Alberico, Ray, Kausik K., Mikhailidis, Dimitri P., Toth, Peter P., Howard, George, Lip, Gregory Y. H., Tomaszewski, Maciej, Charchar, Fadi J., Sattar, Naveed, Williams, Bryan, MacDonald, Thomas M., Penson, Peter E., and Jóźwiak, Jacek J.

Published
2022
Full Text
View/download PDF

20. Carotid Plaque-RADS: A Novel Stroke Risk Classification System

Author

Brain, MS Radiologie, Saba, Luca, Cau, Riccardo, Murgia, Alessandro, Nicolaides, Andrew N., Wintermark, Max, Castillo, Mauricio, Staub, Daniel, Kakkos, Stavros K., Yang, Qi, Paraskevas, Kosmas I., Yuan, Chun, Edjlali, Myriam, Sanfilippo, Roberto, Hendrikse, Jeroen, Johansson, Elias, Mossa-Basha, Mahmud, Balu, Niranjan, Dichgans, Martin, Saloner, David, Bos, Daniel, Jager, H. Rolf, Naylor, Ross, Faa, Gavino, Suri, Jasjit S., Costello, Justin, Auer, Dorothee P., Mcnally, J. Scott, Bonati, Leo H., Nardi, Valentina, van der Lugt, Aad, Griffin, Maura, Wasserman, Bruce A., Kooi, M. Eline, Gillard, Jonathan, Lanzino, Giuseppe, Mikhailidis, Dimitri P., Mandell, Daniel M., Benson, John C., van Dam-Nolen, Dianne H.K., Kopczak, Anna, Song, Jae W., Gupta, Ajay, DeMarco, J. Kevin, Chaturvedi, Seemant, Virmani, Renu, Hatsukami, Thomas S., Brown, Martin, Moody, Alan R., Libby, Peter, Schindler, Andreas, Saam, Tobias, Brain, MS Radiologie, Saba, Luca, Cau, Riccardo, Murgia, Alessandro, Nicolaides, Andrew N., Wintermark, Max, Castillo, Mauricio, Staub, Daniel, Kakkos, Stavros K., Yang, Qi, Paraskevas, Kosmas I., Yuan, Chun, Edjlali, Myriam, Sanfilippo, Roberto, Hendrikse, Jeroen, Johansson, Elias, Mossa-Basha, Mahmud, Balu, Niranjan, Dichgans, Martin, Saloner, David, Bos, Daniel, Jager, H. Rolf, Naylor, Ross, Faa, Gavino, Suri, Jasjit S., Costello, Justin, Auer, Dorothee P., Mcnally, J. Scott, Bonati, Leo H., Nardi, Valentina, van der Lugt, Aad, Griffin, Maura, Wasserman, Bruce A., Kooi, M. Eline, Gillard, Jonathan, Lanzino, Giuseppe, Mikhailidis, Dimitri P., Mandell, Daniel M., Benson, John C., van Dam-Nolen, Dianne H.K., Kopczak, Anna, Song, Jae W., Gupta, Ajay, DeMarco, J. Kevin, Chaturvedi, Seemant, Virmani, Renu, Hatsukami, Thomas S., Brown, Martin, Moody, Alan R., Libby, Peter, Schindler, Andreas, and Saam, Tobias

Published
2024

21. An international, multispecialty, expert-based Delphi Consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis

Author

Zorgeenheid Vaatchirurgie Medisch, Circulatory Health, Regenerative Medicine and Stem Cells, Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Ringleb, Peter Arthur, Brown, Martin M., Dardik, Alan, Poredos, Pavel, Gray, William A., Nicolaides, Andrew N., Lal, Brajesh K., Mansilha, Armando, Antignani, Pier Luigi, de Borst, Gert J., Cambria, Richard P., Loftus, Ian M., Lavie, Carl J., Blinc, Ales, Lyden, Sean P., Matsumura, Jon S., Jezovnik, Mateja K., Bacharach, J. Michael, Meschia, James F., Clair, Daniel G., Zeebregts, Clark J., Lanza, Gaetano, Capoccia, Laura, Spinelli, Francesco, Liapis, Christos D., Jawien, Arkadiusz, Parikh, Sahil A., Svetlikov, Alexei, Menyhei, Gabor, Davies, Alun H., Musialek, Piotr, Roubin, Gary, Stilo, Francesco, Sultan, Sherif, Proczka, Robert M., Faggioli, Gianluca, Geroulakos, George, Fernandes e Fernandes, Jose, Ricco, Jean Baptiste, Saba, Luca, Secemsky, Eric A., Pini, Rodolfo, Myrcha, Piotr, Rundek, Tatjana, Martinelli, Ombretta, Kakkos, Stavros K., Sachar, Ravish, Goudot, Guillaume, Schlachetzki, Felix, Lavenson, George S., Ricci, Stefano, Topakian, Raffi, Millon, Antoine, Di Lazzaro, Vincenzo, Silvestrini, Mauro, Chaturvedi, Seemant, Eckstein, Hans Henning, Gloviczki, Peter, White, Christopher J., Zorgeenheid Vaatchirurgie Medisch, Circulatory Health, Regenerative Medicine and Stem Cells, Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Ringleb, Peter Arthur, Brown, Martin M., Dardik, Alan, Poredos, Pavel, Gray, William A., Nicolaides, Andrew N., Lal, Brajesh K., Mansilha, Armando, Antignani, Pier Luigi, de Borst, Gert J., Cambria, Richard P., Loftus, Ian M., Lavie, Carl J., Blinc, Ales, Lyden, Sean P., Matsumura, Jon S., Jezovnik, Mateja K., Bacharach, J. Michael, Meschia, James F., Clair, Daniel G., Zeebregts, Clark J., Lanza, Gaetano, Capoccia, Laura, Spinelli, Francesco, Liapis, Christos D., Jawien, Arkadiusz, Parikh, Sahil A., Svetlikov, Alexei, Menyhei, Gabor, Davies, Alun H., Musialek, Piotr, Roubin, Gary, Stilo, Francesco, Sultan, Sherif, Proczka, Robert M., Faggioli, Gianluca, Geroulakos, George, Fernandes e Fernandes, Jose, Ricco, Jean Baptiste, Saba, Luca, Secemsky, Eric A., Pini, Rodolfo, Myrcha, Piotr, Rundek, Tatjana, Martinelli, Ombretta, Kakkos, Stavros K., Sachar, Ravish, Goudot, Guillaume, Schlachetzki, Felix, Lavenson, George S., Ricci, Stefano, Topakian, Raffi, Millon, Antoine, Di Lazzaro, Vincenzo, Silvestrini, Mauro, Chaturvedi, Seemant, Eckstein, Hans Henning, Gloviczki, Peter, and White, Christopher J.

Published
2024

30. Are We Using Ezetimibe As Much As We Should?

Author

Manolis, Antonis A, Manolis, Theodora A, Mikhailidis, Dimitri P, and Manolis, Antonis S

Subjects
EZETIMIBE, LDL cholesterol, STATINS (Cardiovascular agents), LOW density lipoproteins, CONTRAST media
Abstract

Lipid-lowering therapies, particularly non-statin regimens, are underutilized as ~2/3 of patients with atherosclerotic cardiovascular (CV) disease (CVD) are not optimally managed, and do not attain target low-density lipoprotein cholesterol (LDL-C) concentrations, despite statin treatment. Statins have been the mainstay of hypolipidemic therapies; however, they are plagued by adverse effects, which have partly hindered their more widespread use. Ezetimibe is often the first added mode of treatment to attain LDL-C goals as it is efficacious and also allows the use of a smaller dose of statin, while the need for more expensive therapies is obviated. We herein provide a comprehensive review of the effects of ezetimibe in lipid lowering and reducing CV events and improving outcomes. Of the hypolipidemic therapies, oral ezetimibe, in contrast to newer agents, is the most convenient and/or affordable regimen to be utilized as mono- or combined therapy supported by data from CV outcomes studies attesting to its efficacy in reducing CVD risk and events. When combined with a statin, the statin dose could be lower, thus curtailing side-effects, while the hypolipidemic effect is enhanced (by ~20%) as the percentage of patients with target level LDL-C (<70 mg/dL) is higher with combined treatment versus a high-intensity statin. Ezetimibe could also serve as an alternative treatment in cases of statin intolerance. In conclusion, ezetimibe has an excellent safety/tolerability profile; it is the first added treatment to a statin that can attain LDL-C targets. In the combined therapy, the hypolipidemic effect is enhanced while the dose of statin could be lower, thus limiting the occurrence of side-effects. Ezetimibe could also serve as an alternative mode of treatment in cases of statin intolerance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Thyroid Disorders and Peripheral Arterial Disease

Author

Studen, Katica Bajuk, primary, Gaberscek, Simona, additional, Zaletel, Katja, additional, Blinc, Ales, additional, Sabovic, Miso, additional, Schernthaner, Gerit-Holger, additional, Anagnostis, Panagiotis, additional, Antignani, Pier Luigi, additional, Jensterle, Mojca, additional, Mikhailidis, Dimitri P., additional, and Poredos, Pavel, additional

Published
2023
Full Text
View/download PDF

33. An international, multispecialty, expert-based Delphi Consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis

Author

Paraskevas, Kosmas I., primary, Mikhailidis, Dimitri P., additional, Ringleb, Peter Arthur, additional, Brown, Martin M., additional, Dardik, Alan, additional, Poredos, Pavel, additional, Gray, William A., additional, Nicolaides, Andrew N., additional, Lal, Brajesh K., additional, Mansilha, Armando, additional, Antignani, Pier Luigi, additional, de Borst, Gert J., additional, Cambria, Richard P., additional, Loftus, Ian M., additional, Lavie, Carl J., additional, Blinc, Ales, additional, Lyden, Sean P., additional, Matsumura, Jon S., additional, Jezovnik, Mateja K., additional, Bacharach, J. Michael, additional, Meschia, James F., additional, Clair, Daniel G., additional, Zeebregts, Clark J., additional, Lanza, Gaetano, additional, Capoccia, Laura, additional, Spinelli, Francesco, additional, Liapis, Christos D., additional, Jawien, Arkadiusz, additional, Parikh, Sahil A., additional, Svetlikov, Alexei, additional, Menyhei, Gabor, additional, Davies, Alun H., additional, Musialek, Piotr, additional, Roubin, Gary, additional, Stilo, Francesco, additional, Sultan, Sherif, additional, Proczka, Robert M., additional, Faggioli, Gianluca, additional, Geroulakos, George, additional, Fernandes e Fernandes, Jose, additional, Ricco, Jean-Baptiste, additional, Saba, Luca, additional, Secemsky, Eric A., additional, Pini, Rodolfo, additional, Myrcha, Piotr, additional, Rundek, Tatjana, additional, Martinelli, Ombretta, additional, Kakkos, Stavros K., additional, Sachar, Ravish, additional, Goudot, Guillaume, additional, Schlachetzki, Felix, additional, Lavenson, George S., additional, Ricci, Stefano, additional, Topakian, Raffi, additional, Millon, Antoine, additional, Di Lazzaro, Vincenzo, additional, Silvestrini, Mauro, additional, Chaturvedi, Seemant, additional, Eckstein, Hans-Henning, additional, Gloviczki, Peter, additional, and White, Christopher J., additional

Published
2023
Full Text
View/download PDF

35. Recent advances and controversial issues in the optimal management of asymptomatic carotid stenosis

Author

Paraskevas, Kosmas I., primary, Brown, Martin M., additional, Lal, Brajesh K., additional, Myrcha, Piotr, additional, Lyden, Sean P., additional, Schneider, Peter A., additional, Poredos, Pavel, additional, Mikhailidis, Dimitri P., additional, Secemsky, Eric A., additional, Musialek, Piotr, additional, Mansilha, Armando, additional, Parikh, Sahil A., additional, Silvestrini, Mauro, additional, Lavie, Carl J., additional, Dardik, Alan, additional, Blecha, Matthew, additional, Liapis, Christos D., additional, Zeebregts, Clark J., additional, Nederkoorn, Paul J., additional, Poredos, Peter, additional, Gurevich, Victor, additional, Jawien, Arkadiusz, additional, Lanza, Gaetano, additional, Gray, William A., additional, Gupta, Ajay, additional, Svetlikov, Alexei V., additional, Fernandes e Fernandes, Jose, additional, Nicolaides, Andrew N., additional, White, Christopher J., additional, Meschia, James F., additional, Cronenwett, Jack L., additional, Schermerhorn, Marc L., additional, and AbuRahma, Ali F., additional

Published
2023
Full Text
View/download PDF

36. Personalized Medicine for Cardiovascular Disease Risk in Artificial Intelligence Framework

Author

Singh, Manasvi, primary, Kumar, Ashish, additional, Khanna, Narendra N., additional, Laird, John R., additional, Nicolaides, Andrew, additional, Faa, Gavino, additional, Johri, Amer M., additional, Mantella, Laura E., additional, Fernandes, Jose, additional, Teji, Jagjit S., additional, Singh, Narpinder, additional, Fouda, Mostafa M., additional, Sharma, Aditya, additional, Kitas, George, additional, Rathore, Vijay, additional, Singh, Inder M., additional, Tadepalli, Kalyan, additional, Al-Maini, Mustafa, additional, Isenovic, Esma R., additional, Chaturvedi, Seemant, additional, Paraskevas, Kosmas I., additional, Mikhailidis, Dimitri P., additional, Viswanathan, Vijay, additional, Kalra, Manudeep K, additional, Ruzsa, Zoltan, additional, Saba, Luca, additional, Laine, Andrew F., additional, Bhatt, Deepak L., additional, and Suri, Jasjit S., additional

Published
2023
Full Text
View/download PDF

37. Carotid Plaque-RADS, a novel stroke risk classification system

Author

Saba, Luca, primary, Cau, Riccardo, additional, Murgia, Alessandro, additional, Nicolaides, Andrew N., additional, Wintermark, Max, additional, Castillo, Mauricio, additional, Staub, Daniel, additional, Kakkos, Stravos, additional, Yang, Qi, additional, Paraskevas, Kosmas I., additional, Yuan, Chun, additional, Edjlali, Myriam, additional, Sanfilippo, Roberto, additional, Hendrikse, Jeroen, additional, Johansson, Elias, additional, Mossa-Basha, Mamood, additional, Balu, Niranjan, additional, Dichgans, Martin, additional, Saloner, David, additional, Bos, Daniel, additional, Jager, Rolf H., additional, Naylor, Ross, additional, Faa, Gavino, additional, Suri, Jasjit S., additional, Costello, Justin, additional, Auer, Dorothee P., additional, McNally, Scott, additional, Bonati, Leo H., additional, Nardi, Valentina, additional, van der Lugt, Aad, additional, Griffin, Maura, additional, Wasserman, Bruce A., additional, Kooi, M. Eline, additional, Gillard, Jonathan, additional, Lanzino, Giuseppe, additional, Mikhailidis, Dimitri P., additional, Mandell, Danny M., additional, Benson, John, additional, van Dam-Nolen, Dianne, additional, Kopczak, Anna, additional, Song, Jae, additional, Gupta, Ajay, additional, DeMarco, J. Kevin, additional, Chaturvedi, Seemant, additional, Virmani, Renu, additional, Hatsukami, Tom, additional, Brown, Martin, additional, Moody, Alan R., additional, Libby, Peter, additional, Schindler, Andreas, additional, and Saam, Tobias, additional

Published
2023
Full Text
View/download PDF

38. Cardiometabolic Risk, Peripheral Arterial Disease and Cardiovascular Events in Polycystic Ovary Syndrome: Time to Implement Systematic Screening and Update the Management

Author

Janez, Andrej, primary, Herman, Rok, additional, Poredos, Pavel, additional, Mikhailidis, Dimitri P., additional, Blinc, Ales, additional, Sabovic, Miso, additional, Studen, Katica Bajuk, additional, Jezovnik, Mateja Kaja, additional, Schernthaner, Gerit-Holger, additional, Anagnostis, Panagiotis, additional, Antignani, Pier Luigi, additional, and Jensterle, Mojca, additional

Published
2023
Full Text
View/download PDF

43. Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview

Author

Telci Caklili,Ozge, Cesur,Mustafa, Mikhailidis,Dimitri P, Rizzo,Manfredi, Telci Caklili,Ozge, Cesur,Mustafa, Mikhailidis,Dimitri P, and Rizzo,Manfredi

Abstract

Ozge Telci Caklili,1 Mustafa Cesur,2 Dimitri P Mikhailidis,3 Manfredi Rizzo4 1Department of Endocrinology and Metabolism, Faculty of Medicine, University of Istanbul, Istanbul, Türkiye; 2Department of Endocrinology and Metabolism, Ankara Guven University Hospital, Ankara, Türkiye; 3Department of Clinical Biochemistry and Department of Surgical Biotechnology, Division of Surgery and Interventional Science, Medical School, University College London (UCL), London, UK; 4School of Medicine, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Palermo, ItalyCorrespondence: Manfredi Rizzo, School of Medicine, Promise Department, University of Palermo, Via del Vespro 141, Palermo, 90127, Italy, Tel/Fax +39 091 655-2945, Email manfredi.rizzo@unipa.itAbstract: Obesity has become an epidemic and a worldwide problem and its treatment is ever-evolving. Apart from diet and exercise, medication and surgery are other options. After disappointing side effects of various obesity drugs, new treatments showed promising results. This review discusses the following anti-obesity drugs: liraglutide, semaglutide, tirzepatide, orlistat, as well as the phentermine/topiramate and bupropion/naltrexone combinations. These drugs have been approved by the Food and Drug Administration (FDA) for weight reduction except for tirzepatide which is still under evaluation. Efficacy and tolerable safety profiles of some of these drugs contribute to the management of obesity and reduce the complications associated with this chronic disease.Keywords: obesity, drugs, liraglutide, semaglutide, tirzepatide, orlistat, phentermine/topiramate, bupropion/naltrexone

Published
2023

44. Metabolic syndrome is associated with similar long-term prognosis in non-obese and obese patients. An analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004-2015 cohort studies

Author

Osadnik, Kamila, Osadnik, Tadeusz, Gierlotka, Marek, Windak, Adam, Tomasik, Tomasz, Mastej, Mirosław, Kuras, Agnieszka, Jóźwiak, Kacper, Penson, Peter E., Lip, Gregory Y. H., Mikhailidis, Dimitri P., Toth, Peter P., Catapano, Alberico L., Ray, Kausik K., Howard, George, Tomaszewski, Maciej, Charchar, Fadi J., Sattar, Naveed, Williams, Bryan, MacDonald, Thomas M., Banach, Maciej, and Jóźwiak, Jacek

Abstract

Aims: We aimed to evaluate the association between metabolic syndrome (MetS) and long-term all-cause mortality.Methods: The LIPIDOGRAM studies were carried out in the primary care in Poland in 2004, 2006 and 2015. MetS was diagnosed based on the National Cholesterol Education Program, Adult Treatment Panel III (NCEP/ATP III) and Joint Interim Statement (JIS) criteria. The cohort was divided into four groups: non-obese patients without MetS, obese patients without MetS, non-obese patients with MetS and obese patients with MetS. Differences in all-cause mortality was analyzed using Kaplan-Meier and Cox regression analyses.Results: 45,615 participants were enrolled (mean age 56.3, standard deviation: 11.8 years; 61.7% female). MetS was diagnosed in 14,202 (31%) by NCEP/ATP III criteria, and 17,216 (37.7%) by JIS criteria. Follow-up was available for 44,620 (97.8%, median duration 15.3 years) patients. MetS was associated with increased mortality risk among the obese (hazard ratio, HR: 1.88 [95% CI, 1.79-1.99] and HR: 1.93 [95% CI 1.82-2.04], according to NCEP/ATP III and JIS criteria, respectively) and non-obese individuals (HR: 2.11 [95% CI 1.85-2.40] and 1.7 [95% CI, 1.56-1.85] according to NCEP/ATP III and JIS criteria respectively). Obese patients without MetS had a higher mortality risk than non-obese patients without MetS (HR: 1.16 [95% CI 1.10-1.23] and HR: 1.22 [95%CI 1.15-1.30], respectively in subgroups with NCEP/ATP III and JIS criteria applied).Conclusions: MetS is associated with increased all-cause mortality risk in non-obese and obese patients. In patients without MetS obesity remains significantly associated with mortality. The concept of metabolically healthy obesity should be revised. Aims: We aimed to evaluate the association between metabolic syndrome (MetS) and long-term all-cause mortality.Methods: The LIPIDOGRAM studies were carried out in the primary care in Poland in 2004, 2006 and 2015. MetS was diagnosed based on the National Cholesterol Education Program, Adult Treatment Panel III (NCEP/ATP III) and Joint Interim Statement (JIS) criteria. The cohort was divided into four groups: non-obese patients without MetS, obese patients without MetS, non-obese patients with MetS and obese patients with MetS. Differences in all-cause mortality was analyzed using Kaplan-Meier and Cox regression analyses.Results: 45,615 participants were enrolled (mean age 56.3, standard deviation: 11.8 years; 61.7% female). MetS was diagnosed in 14,202 (31%) by NCEP/ATP III criteria, and 17,216 (37.7%) by JIS criteria. Follow-up was available for 44,620 (97.8%, median duration 15.3 years) patients. MetS was associated with increased mortality risk among the obese (hazard ratio, HR: 1.88 [95% CI, 1.79-1.99] and HR: 1.93 [95% CI 1.82-2.04], according to NCEP/ATP III and JIS criteria, respectively) and non-obese individuals (HR: 2.11 [95% CI 1.85-2.40] and 1.7 [95% CI, 1.56-1.85] according to NCEP/ATP III and JIS criteria respectively). Obese patients without MetS had a higher mortality risk than non-obese patients without MetS (HR: 1.16 [95% CI 1.10-1.23] and HR: 1.22 [95%CI 1.15-1.30], respectively in subgroups with NCEP/ATP III and JIS criteria applied).Conclusions: MetS is associated with increased all-cause mortality risk in non-obese and obese patients. In patients without MetS obesity remains significantly associated with mortality. The concept of metabolically healthy obesity should be revised.

Published
2023
Full Text
View/download PDF

45. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

Author

Rizzo, Manfredi, primary, Colletti, Alessandro, additional, Penson, Peter E., additional, Katsiki, Niki, additional, Mikhailidis, Dimitri P., additional, Toth, Peter P., additional, Gouni-Berthold, Ioanna, additional, Mancini, John, additional, Marais, David, additional, Moriarty, Patrick, additional, Ruscica, Massimiliano, additional, Sahebkar, Amirhossein, additional, Vinereanu, Dragos, additional, Cicero, Arrigo Francesco Giuseppe, additional, Banach, Maciej, additional, Acosta, Julio, additional, Al-Khnifsawi, Mutaz, additional, Alnouri, Fahad, additional, Amar, Fahma, additional, Atanasov, Atanas G., additional, Bajraktari, Gani, additional, Bhaskar, Sonu, additional, Bielecka-Dąbrowa, Agata, additional, Bjelakovic, Bojko, additional, Bruckert, Eric, additional, Bytyçi, Ibadete, additional, Cafferata, Alberto, additional, Ceska, Richard, additional, Cicero, Arrigo F.G., additional, Chlebus, Krzysztof, additional, Collet, Xavier, additional, Daccord, Magdalena, additional, Descamps, Olivier, additional, Djuric, Dragan, additional, Durst, Ronen, additional, Ezhov, Marat V., additional, Fras, Zlatko, additional, Gaita, Dan, additional, Hernandez, Adrian V., additional, Jones, Steven R., additional, Jozwiak, Jacek, additional, Kakauridze, Nona, additional, Kallel, Amani, additional, Khera, Amit, additional, Kostner, Karam, additional, Kubilius, Raimondas, additional, Latkovskis, Gustavs, additional, John Mancini, G.B., additional, David Marais, A., additional, Martin, Seth S., additional, Martinez, Julio Acosta, additional, Mazidi, Mohsen, additional, Mirrakhimov, Erkin, additional, Miserez, Andre R., additional, Mitchenko, Olena, additional, Mitkovskaya, Natalya P., additional, Moriarty, Patrick M., additional, Mohammad Nabavi, Seyed, additional, Nair, Devaki, additional, Panagiotakos, Demosthenes B., additional, Paragh, György, additional, Pella, Daniel, additional, Petrulioniene, Zaneta, additional, Pirro, Matteo, additional, Postadzhiyan, Arman, additional, Puri, Raman, additional, Reda, Ashraf, additional, Reiner, Željko, additional, Radenkovic, Dina, additional, Rakowski, Michał, additional, Riadh, Jemaa, additional, Richter, Dimitri, additional, Rizzo, Manfredi, additional, Serban, Maria-Corina, additional, Shehab, Abdullah M.A, additional, Shek, Aleksandr B., additional, Sirtori, Cesare R., additional, Stefanutti, Claudia, additional, Tomasik, Tomasz, additional, Viigimaa, Margus, additional, Valdivielso, Pedro, additional, Vohnout, Branislav, additional, von Haehling, Stephan, additional, Vrablik, Michal, additional, Wong, Nathan D., additional, Yeh, Hung-I, additional, Zhisheng, Jiang, additional, and Zirlik, Andreas, additional

Published
2023
Full Text
View/download PDF

46. Asymptomatic carotid stenosis and cognitive impairment

Author

PARASKEVAS, Kosmas I., primary, MIKHAILIDIS, Dimitri P., additional, SPINELLI, Francesco, additional, FAGGIOLI, Gianluca, additional, SABA, Luca, additional, SILVESTRINI, Mauro, additional, SVETLIKOV, Alexei, additional, STILO, Francesco, additional, PINI, Rodolfo, additional, MYRCHA, Piotr, additional, DI LAZZARO, Vincenzo, additional, ANTIGNANI, Pier L., additional, POREDOS, Pavel, additional, and LANZA, Gaetano, additional

Published
2023
Full Text
View/download PDF

47. Screening for asymptomatic carotid stenosis in patients with non-valvular atrial fibrillation

Author

Paraskevas, Kosmas I., primary, Eckstein, Hans-Henning, additional, Mansilha, Armando, additional, Ricco, Jean-Baptiste, additional, Geroulakos, George, additional, Di Lazzaro, Vincenzo, additional, Rundek, Tatjana, additional, Lanza, Gaetano, additional, Fraedrich, Gustav, additional, Svetlikov, Alexei S., additional, Suri, Jasjit S., additional, Zeebregts, Clark J., additional, Davies, Alun H., additional, Capoccia, Laura, additional, Proczka, Robert M., additional, Myrcha, Piotr, additional, Antignani, Pier Luigi, additional, Fernandes e Fernandes, Jose, additional, Spence, J. David, additional, Dardik, Alan, additional, Jezovnik, Mateja K., additional, Knoflach, Michael, additional, Lavenson, George S., additional, Kakkos, Stavros K., additional, Jawien, Arkadiusz, additional, Silvestrini, Mauro, additional, Blinc, Aleš, additional, Spinelli, Francesco, additional, Stilo, Francesco, additional, Musiałek, Piotr, additional, Sultan, Sherif, additional, Goudot, Guillaume, additional, Liapis, Christos D., additional, Saba, Luca, additional, Faggioli, Gianluca, additional, Pini, Rodolfo, additional, Poredos, Pavel, additional, Mikhailidis, Dimitri P., additional, Gloviczki, Peter, additional, and Nicolaides, Andrew N., additional

Published
2023
Full Text
View/download PDF

49. Clarifying the rationale supporting selective screening for asymptomatic carotid artery stenosis

Author

Paraskevas, Kosmas I., primary, Nicolaides, Andrew N., additional, Spence, J. David, additional, Mikhailidis, Dimitri P., additional, Lanza, Gaetano, additional, Liapis, Christos D., additional, Goudot, Guillaume, additional, Faggioli, Gianluca, additional, Pini, Rodolfo, additional, Musiałek, Piotr, additional, Suri, Jasjit S., additional, Silvestrini, Mauro, additional, Fernandes e Fernandes, Jose, additional, Eckstein, Hans-Henning, additional, Jawien, Arkadiusz, additional, Spinelli, Francesco, additional, Stilo, Francesco, additional, Myrcha, Piotr, additional, Rundek, Tatjana, additional, Kakkos, Stavros K., additional, Di Lazzaro, Vincenzo, additional, Svetlikov, Alexei, additional, Antignani, Pier Luigi, additional, Poredos, Pavel, additional, Saba, Luca, additional, Jezovnik, Mateja K., additional, Blinc, Aleš, additional, Sultan, Sherif, additional, Knoflach, Michael, additional, Capoccia, Laura, additional, Proczka, Robert M., additional, Fraedrich, Gustav, additional, Zeebregts, Clark J., additional, Davies, Alun H., additional, Geroulakos, George, additional, Ricco, Jean-Baptiste, additional, Mansilha, Armando, additional, Dardik, Alan, additional, and Gloviczki, Peter, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results